CoChat

PALB2: The hub of a network of tumor suppressors involved in DNA damage responses

Open access
Park, Jung-Young, Zhang, Fan, Andreassen, Paul R. · 2014 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Cited by 78

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Abstract

PALB2 was first identified as a partner of BRCA2 that mediates its recruitment to sites of DNA damage. PALB2 was subsequently found as a tumor suppressor gene. Inherited heterozygosity for this gene is associated with an increased risk of cancer of the breast and other sites. Additionally, biallelic mutation of PALB2 is linked to Fanconi anemia, which also has an increased risk of developing malignant disease. Recent work has identified numerous interactions of PALB2, suggesting that it functions in a network of proteins encoded by tumor suppressors. Notably, many of these tumor suppressors are related to the cellular response to DNA damage. The recruitment of PALB2 to DNA double-strand breaks at the head of this network is via a ubiquitin-dependent signaling pathway that involves the RAP80, Abraxas and BRCA1 tumor suppressors. Next, PALB2 interacts with BRCA2, which is a tumor suppressor, and with the RAD51 recombinase. These interactions promote DNA repair by homologous recombination (HR). More recently, PALB2 has been found to bind the RAD51 paralog, RAD51C, as well as the translesion polymerase pol η, both of which are tumor suppressors with functions in HR. Further, an interaction with MRG15, which is related to chromatin regulation, may facilitate DNA repair in damaged chromatin. Finally, PALB2 interacts with KEAP1, a regulator of the response to oxidative stress. The PALB2 network appears to mediate the maintenance of genome stability, may explain the association of many of the corresponding genes with similar spectra of tumors, and could present novel therapeutic opportunities.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbcan.2014.06.003

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Research works printed but not linked: 131

  1. Moynahan, 2010, Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis, Nat. Rev. Mol. Cell Biol., 11, 196, 10.1038/nrm2851 · DOI · Paper page
  2. Park, 2012, Rare mutations in XRCC2 increase the risk of breast cancer, Am. J. Hum. Genet., 90, 734, 10.1016/j.ajhg.2012.02.027 · DOI · Paper page
  3. Meindl, 2010, Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene, Nat. Genet., 42, 410, 10.1038/ng.569 · DOI · Paper page
  4. Vuorela, 2011, Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility, Breast Cancer Res. Treat., 130, 1003, 10.1007/s10549-011-1677-x · DOI
  5. Miki, 1994, A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science, 266, 66, 10.1126/science.7545954 · DOI · Paper page
  6. Wooster, 1995, Identification of the breast cancer susceptibility gene BRCA2, Nature, 378, 789, 10.1038/378789a0 · DOI · Paper page
  7. Pal, 2005, BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases, Cancer, 104, 2807, 10.1002/cncr.21536 · DOI · Paper page
  8. Moran, 2012, Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations, Fam. Cancer, 11, 235, 10.1007/s10689-011-9506-2 · DOI · Paper page
  9. Lal, 2000, Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations, Cancer Res., 60, 409
  10. Scully, 2013, Double strand break repair functions of histone H2AX, Mutat. Res., 750, 5, 10.1016/j.mrfmmm.2013.07.007 · DOI · Paper page
  11. Mimitou, 2009, DNA end resection: many nucleases make light work, DNA Repair, 8, 983, 10.1016/j.dnarep.2009.04.017 · DOI · Paper page
  12. Suwaki, 2011, RAD51 paralogs: roles in DNA damage signalling, recombinational repair and tumorigenesis, Semin. Cell Dev. Biol., 22, 898, 10.1016/j.semcdb.2011.07.019 · DOI · Paper page
  13. Chen, 2008, Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair, J. Biol. Chem., 283, 7713, 10.1074/jbc.M710245200 · DOI · Paper page
  14. Coleman, 2011, The BRCA1-RAP80 complex regulates DNA repair mechanism utilization by restricting end resection, J. Biol. Chem., 286, 13669, 10.1074/jbc.M110.213728 · DOI · Paper page
  15. Kitagawa, 2004, Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway, Genes Dev., 18, 1423, 10.1101/gad.1200304 · DOI · Paper page
  16. Moynahan, 2001, Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation, Cancer Res., 61, 4842
  17. Barker, 2010, Enhancing radiotherapy through a greater understanding of homologous recombination, Semin. Radiat. Oncol., 20, 267, 10.1016/j.semradonc.2010.05.001 · DOI
  18. Stoepker, 2011, SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype, Nat. Genet., 43, 138, 10.1038/ng.751 · DOI · Paper page
  19. Kim, 2011, Mutations of the SLX4 gene in Fanconi anemia, Nat. Genet., 43, 142, 10.1038/ng.750 · DOI · Paper page
  20. Bogliolo, 2013, Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia, Am. J. Hum. Genet., 92, 800, 10.1016/j.ajhg.2013.04.002 · DOI · Paper page
  21. de Winter, 2000, Isolation of a cDNA representing the Fanconi anemia complementation group E gene, Am. J. Hum. Genet., 67, 1306, 10.1016/S0002-9297(07)62959-0 · DOI · Paper page
  22. de Winter, 2000, The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM, Nat. Genet., 24, 15, 10.1038/71626 · DOI · Paper page
  23. de Winter, 1998, The Fanconi anaemia group G gene FANCG is identical with XRCC9, Nat. Genet., 20, 281, 10.1038/3093 · DOI · Paper page
  24. Dorsman, 2007, Identification of the Fanconi anemia complementation group I gene, FANCI, Cell. Oncol., 29, 211
  25. c. Fanconi anaemia/Breast cancer, 1996, Positional cloning of the Fanconi anaemia group A gene, Nat. Genet., 14, 324, 10.1038/ng1196-324 · DOI · Paper page
  26. Lo Ten Foe, 1996, Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA, Nat. Genet., 14, 320, 10.1038/ng1196-320 · DOI · Paper page
  27. Sims, 2007, FANCI is a second monoubiquitinated member of the Fanconi anemia pathway, Nat. Struct. Mol. Biol., 14, 564, 10.1038/nsmb1252 · DOI · Paper page
  28. Smogorzewska, 2007, Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair, Cell, 129, 289, 10.1016/j.cell.2007.03.009 · DOI · Paper page
  29. Strathdee, 1992, Cloning of cDNAs for Fanconi's anaemia by functional complementation, Nature, 356, 763, 10.1038/356763a0 · DOI · Paper page
  30. Timmers, 2001, Positional cloning of a novel Fanconi anemia gene, FANCD2, Mol. Cell, 7, 241, 10.1016/S1097-2765(01)00172-1 · DOI · Paper page
  31. Meetei, 2003, A novel ubiquitin ligase is deficient in Fanconi anemia, Nat. Genet., 35, 165, 10.1038/ng1241 · DOI · Paper page
  32. Meetei, 2004, X-linked inheritance of Fanconi anemia complementation group B, Nat. Genet., 36, 1219, 10.1038/ng1458 · DOI · Paper page
  33. Meetei, 2005, A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M, Nat. Genet., 37, 958, 10.1038/ng1626 · DOI · Paper page
  34. Kee, 2012, Molecular pathogenesis and clinical management of Fanconi anemia, J. Clin. Invest., 122, 3799, 10.1172/JCI58321 · DOI · Paper page
  35. Kottemann, 2013, Fanconi anaemia and the repair of Watson and Crick DNA crosslinks, Nature, 493, 356, 10.1038/nature11863 · DOI · Paper page
  36. Andreassen, 2009, Fanconi anemia proteins, DNA interstrand crosslink repair pathways, and cancer therapy, Curr. Cancer Drug Targets, 9, 101, 10.2174/156800909787314011 · DOI
  37. Nakanishi, 2011, Homology-directed Fanconi anemia pathway cross-link repair is dependent on DNA replication, Nat. Struct. Mol. Biol., 18, 500, 10.1038/nsmb.2029 · DOI · Paper page
  38. Rahman, 2007, PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene, Nat. Genet., 39, 165, 10.1038/ng1959 · DOI · Paper page
  39. Erkko, 2007, A recurrent mutation in PALB2 in Finnish cancer families, Nature, 446, 316, 10.1038/nature05609 · DOI · Paper page
  40. Takata, 2001, Chromosome instability and defective recombinational repair in knockout mutants of the five Rad51 paralogs, Mol. Cell. Biol., 21, 2858, 10.1128/MCB.21.8.2858-2866.2001 · DOI · Paper page
  41. Abbott, 1998, Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells, J. Natl. Cancer Inst., 90, 978, 10.1093/jnci/90.13.978 · DOI · Paper page
  42. Ghosh, 2014, Hypersensitivities for acetaldehyde and other agents among cancer cells null for clinically relevant Fanconi anemia genes, Am. J. Pathol., 184, 260, 10.1016/j.ajpath.2013.09.023 · DOI
  43. Park, 2013, Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair, Oncogene
  44. Tischkowitz, 2007, Analysis of PALB2/FANCN-associated breast cancer families, Proc. Natl. Acad. Sci. U. S. A., 104, 6788, 10.1073/pnas.0701724104 · DOI · Paper page
  45. Zhang, 2012, MDC1 and RNF8 function in a pathway that directs BRCA1-dependent localization of PALB2 required for homologous recombination, J. Cell Sci., 125, 6049, 10.1242/jcs.111872 · DOI
  46. Zhang, 2009, PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2, Mol. Cancer Res., 7, 1110, 10.1158/1541-7786.MCR-09-0123 · DOI · Paper page
  47. Zhang, 2009, PALB2 links BRCA1 and BRCA2 in the DNA-damage response, Curr. Biol., 19, 524, 10.1016/j.cub.2009.02.018 · DOI · Paper page
  48. Hayakawa, 2010, MRG15 binds directly to PALB2 and stimulates homology-directed repair of chromosomal breaks, J. Cell Sci., 123, 1124, 10.1242/jcs.060178 · DOI · Paper page
  49. Sy, 2009, PALB2 is an integral component of the BRCA complex required for homologous recombination repair, Proc. Natl. Acad. Sci. U. S. A., 106, 7155, 10.1073/pnas.0811159106 · DOI · Paper page
  50. Sy, 2009, PALB2 regulates recombinational repair through chromatin association and oligomerization, J. Biol. Chem., 284, 18302, 10.1074/jbc.M109.016717 · DOI
  51. Oliver, 2009, Structural basis for recruitment of BRCA2 by PALB2, EMBO Rep., 10, 990, 10.1038/embor.2009.126 · DOI · Paper page
  52. Tischkowitz, 2010, PALB2/FANCN: recombining cancer and Fanconi anemia, Cancer Res., 70, 7353, 10.1158/0008-5472.CAN-10-1012 · DOI · Paper page
  53. Sy, 2009, MRG15 is a novel PALB2-interacting factor involved in homologous recombination, J. Biol. Chem., 284, 21127, 10.1074/jbc.C109.023937 · DOI · Paper page
  54. Martrat, 2011, Exploring the link between MORF4L1 and risk of breast cancer, Breast Cancer Res., 13, R40, 10.1186/bcr2862 · DOI
  55. Ma, 2012, PALB2 interacts with KEAP1 to promote NRF2 nuclear accumulation and function, Mol. Cell. Biol., 32, 1506, 10.1128/MCB.06271-11 · DOI · Paper page
  56. Hast, 2013, Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination, Cancer Res., 73, 2199, 10.1158/0008-5472.CAN-12-4400 · DOI · Paper page
  57. Hayes, 2009, NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer, Trends Biochem. Sci., 34, 176, 10.1016/j.tibs.2008.12.008 · DOI · Paper page
  58. Fruehauf, 2007, Reactive oxygen species: a breath of life or death?, Clin. Cancer Res., 13, 789, 10.1158/1078-0432.CCR-06-2082 · DOI · Paper page
  59. Sosa, 2013, Oxidative stress and cancer: an overview, Ageing Res. Rev., 12, 376, 10.1016/j.arr.2012.10.004 · DOI · Paper page
  60. Lupas, 1996, Coiled coils: new structures and new functions, Trends Biochem. Sci., 21, 375, 10.1016/S0968-0004(96)10052-9 · DOI · Paper page
  61. Scully, 1997, Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage, Cell, 90, 425, 10.1016/S0092-8674(00)80503-6 · DOI · Paper page
  62. Yuan, 1999, BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo, Cancer Res., 59, 3547
  63. Moynahan, 2001, BRCA2 is required for homology-directed repair of chromosomal breaks, Mol. Cell, 7, 263, 10.1016/S1097-2765(01)00174-5 · DOI · Paper page
  64. Mermershtain, 2013, Structural mechanisms underlying signaling in the cellular response to DNA double strand breaks, Mutat. Res., 750, 15, 10.1016/j.mrfmmm.2013.07.004 · DOI
  65. Huen, 2007, RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly, Cell, 131, 901, 10.1016/j.cell.2007.09.041 · DOI · Paper page
  66. Kolas, 2007, Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase, Science, 318, 1637, 10.1126/science.1150034 · DOI · Paper page
  67. Mailand, 2007, RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins, Cell, 131, 887, 10.1016/j.cell.2007.09.040 · DOI · Paper page
  68. Sobhian, 2007, RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites, Science, 316, 1198, 10.1126/science.1139516 · DOI · Paper page
  69. Buisson, 2012, PALB2 self-interaction controls homologous recombination, Nucleic Acids Res., 40, 10312, 10.1093/nar/gks807 · DOI
  70. Dray, 2010, Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2, Nat. Struct. Mol. Biol., 17, 1255, 10.1038/nsmb.1916 · DOI · Paper page
  71. Buisson, 2010, Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination, Nat. Struct. Mol. Biol., 17, 1247, 10.1038/nsmb.1915 · DOI · Paper page
  72. Itoh, 1999, Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain, Genes Dev., 13, 76, 10.1101/gad.13.1.76 · DOI · Paper page
  73. Klaunig, 2010, Oxidative stress and oxidative damage in carcinogenesis, Toxicol. Pathol., 38, 96, 10.1177/0192623309356453 · DOI · Paper page
  74. Yang, 2002, BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure, Science, 297, 1837, 10.1126/science.297.5588.1837 · DOI · Paper page
  75. Siaud, 2011, Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains, PLoS Genet., 7, e1002409, 10.1371/journal.pgen.1002409 · DOI · Paper page
  76. Esashi, 2007, Stabilization of RAD51 nucleoprotein filaments by the C-terminal region of BRCA2, Nat. Struct. Mol. Biol., 14, 468, 10.1038/nsmb1245 · DOI · Paper page
  77. Martin, 2007, RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors, Cancer Res., 67, 9658, 10.1158/0008-5472.CAN-07-0290 · DOI · Paper page
  78. Yata, 2012, Plk1 and CK2 act in concert to regulate Rad51 during DNA double strand break repair, Mol. Cell, 45, 371, 10.1016/j.molcel.2011.12.028 · DOI · Paper page
  79. Antoniou, 2007, RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies, Am. J. Hum. Genet., 81, 1186, 10.1086/522611 · DOI · Paper page
  80. Bleuyard, 2012, ChAM, a novel motif that mediates PALB2 intrinsic chromatin binding and facilitates DNA repair, EMBO Rep., 13, 135, 10.1038/embor.2011.243 · DOI
  81. Xie, 2012, Structural basis for molecular interactions involving MRG domains: implications in chromatin biology, Structure, 20, 151, 10.1016/j.str.2011.10.019 · DOI
  82. Smeenk, 2013, The chromatin response to DNA breaks: leaving a mark on genome integrity, Annu. Rev. Biochem., 82, 55, 10.1146/annurev-biochem-061809-174504 · DOI · Paper page
  83. Gospodinov, 2013, Shaping chromatin for repair, Mutat. Res., 752, 45, 10.1016/j.mrrev.2012.10.001 · DOI
  84. Chen, 2010, Emerging role of the MORF/MRG gene family in various biological processes, including aging, Ann. N. Y. Acad. Sci., 1197, 134, 10.1111/j.1749-6632.2010.05197.x · DOI
  85. Sapountzi, 2006, Cellular functions of TIP60, Int. J. Biochem. Cell Biol., 38, 1496, 10.1016/j.biocel.2006.03.003 · DOI · Paper page
  86. Ikura, 2007, DNA damage-dependent acetylation and ubiquitination of H2AX enhances chromatin dynamics, Mol. Cell. Biol., 27, 7028, 10.1128/MCB.00579-07 · DOI · Paper page
  87. Yochum, 2002, Role for the mortality factors MORF4, MRGX, and MRG15 in transcriptional repression via associations with Pf1, mSin3A, and Transducin-Like Enhancer of Split, Mol. Cell. Biol., 22, 7868, 10.1128/MCB.22.22.7868-7876.2002 · DOI
  88. Hayakawa, 2007, RBP2 is an MRG15 complex component and down-regulates intragenic histone H3 lysine 4 methylation, Genes Cells, 12, 811, 10.1111/j.1365-2443.2007.01089.x · DOI
  89. Zhang, 2006, Structure of human MRG15 chromo domain and its binding to Lys36-methylated histone H3, Nucleic Acids Res., 34, 6621, 10.1093/nar/gkl989 · DOI · Paper page
  90. Rio Frio, 2010, Mutation analysis of the gene encoding the PALB2-binding protein MRG15 in BRCA1/2-negative breast cancer families, J. Hum. Genet., 55, 842, 10.1038/jhg.2010.112 · DOI
  91. Stirnimann, 2010, WD40 proteins propel cellular networks, Trends Biochem. Sci., 35, 565, 10.1016/j.tibs.2010.04.003 · DOI · Paper page
  92. Buisson, 2014, Breast cancer proteins PALB2 and BRCA2 stimulate polymerase eta in recombination-associated DNA synthesis at blocked replication forks, Cell Rep., 6, 553, 10.1016/j.celrep.2014.01.009 · DOI · Paper page
  93. Menzel, 2011, A genetic screen identifies BRCA2 and PALB2 as key regulators of G2 checkpoint maintenance, EMBO Rep., 12, 705, 10.1038/embor.2011.99 · DOI · Paper page
  94. Phelan, 1996, Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families, Nat. Genet., 13, 120, 10.1038/ng0596-120 · DOI · Paper page
  95. Teng, 1996, Low incidence of BRCA2 mutations in breast carcinoma and other cancers, Nat. Genet., 13, 241, 10.1038/ng0696-241 · DOI · Paper page
  96. Potapova, 2008, Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer, Cancer Res., 68, 998, 10.1158/0008-5472.CAN-07-2418 · DOI
  97. Walsh, 2011, Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing, Proc. Natl. Acad. Sci. U. S. A., 108, 18032, 10.1073/pnas.1115052108 · DOI · Paper page
  98. Hirsch, 2004, Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood, Blood, 103, 2554, 10.1182/blood-2003-06-1970 · DOI · Paper page
  99. Wagner, 2004, Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia, Blood, 103, 3226, 10.1182/blood-2003-09-3138 · DOI · Paper page
  100. Makde, 2010, Structure of RCC1 chromatin factor bound to the nucleosome core particle, Nature, 467, 562, 10.1038/nature09321 · DOI · Paper page
  101. Miller, 2004, Domain mapping of the Rad51 paralog protein complexes, Nucleic Acids Res., 32, 169, 10.1093/nar/gkg925 · DOI
  102. Badie, 2009, RAD51C facilitates checkpoint signaling by promoting CHK2 phosphorylation, J. Cell Biol., 185, 587, 10.1083/jcb.200811079 · DOI · Paper page
  103. Liu, 2004, RAD51C is required for Holliday junction processing in mammalian cells, Science, 303, 243, 10.1126/science.1093037 · DOI · Paper page
  104. Liu, 2002, Involvement of Rad51C in two distinct protein complexes of Rad51 paralogs in human cells, Nucleic Acids Res., 30, 1009, 10.1093/nar/30.4.1009 · DOI · Paper page
  105. Masson, 2001, Identification and purification of two distinct complexes containing the five RAD51 paralogs, Genes Dev., 15, 3296, 10.1101/gad.947001 · DOI · Paper page
  106. Wiese, 2002, Interactions involving the Rad51 paralogs Rad51C and XRCC3 in human cells, Nucleic Acids Res., 30, 1001, 10.1093/nar/30.4.1001 · DOI · Paper page
  107. Schild, 2000, Evidence for simultaneous protein interactions between human Rad51 paralogs, J. Biol. Chem., 275, 16443, 10.1074/jbc.M001473200 · DOI · Paper page
  108. Somyajit, 2012, Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: implications for Fanconi anemia and breast cancer susceptibility, J. Biol. Chem., 287, 3366, 10.1074/jbc.M111.311241 · DOI · Paper page
  109. Hellebrand, 2011, Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer, Hum. Mutat., 32, E2176, 10.1002/humu.21478 · DOI
  110. Liu, 2007, Role of RAD51C and XRCC3 in genetic recombination and DNA repair, J. Biol. Chem., 282, 1973, 10.1074/jbc.M609066200 · DOI · Paper page
  111. Kawamoto, 2005, Dual roles for DNA polymerase eta in homologous DNA recombination and translesion DNA synthesis, Mol. Cell, 20, 793, 10.1016/j.molcel.2005.10.016 · DOI · Paper page
  112. Masutani, 1999, The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta, Nature, 399, 700, 10.1038/21447 · DOI · Paper page
  113. Masutani, 1999, Xeroderma pigmentosum variant (XP-V) correcting protein from HeLa cells has a thymine dimer bypass DNA polymerase activity, EMBO J., 18, 3491, 10.1093/emboj/18.12.3491 · DOI · Paper page
  114. Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  115. Bowman-Colin, 2013, Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer, Proc. Natl. Acad. Sci. U. S. A., 110, 8632, 10.1073/pnas.1305362110 · DOI
  116. Nikkila, 2013, Heterozygous mutations in PALB2 cause DNA replication and damage response defects, Nat. Commun., 4, 2578, 10.1038/ncomms3578 · DOI · Paper page
  117. Schlacher, 2011, Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11, Cell, 145, 529, 10.1016/j.cell.2011.03.041 · DOI · Paper page
  118. Arlt, 2004, BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function, Mol. Cell. Biol., 24, 6701, 10.1128/MCB.24.15.6701-6709.2004 · DOI · Paper page
  119. De Haro, 2010, Metnase promotes restart and repair of stalled and collapsed replication forks, Nucleic Acids Res., 38, 5681, 10.1093/nar/gkq339 · DOI
  120. Bryant, 2005, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, 434, 913, 10.1038/nature03443 · DOI · Paper page
  121. Farmer, 2005, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917, 10.1038/nature03445 · DOI · Paper page
  122. Min, 2013, RAD51C-deficient cancer cells are highly sensitive to the PARP inhibitor olaparib, Mol. Cancer Ther., 12, 865, 10.1158/1535-7163.MCT-12-0950 · DOI · Paper page
  123. Hojfeldt, 2013, Histone lysine demethylases as targets for anticancer therapy, Nat. Rev. Drug Discov., 12, 917, 10.1038/nrd4154 · DOI · Paper page
  124. Zagni, 2013, Histone methyltransferase inhibitors: novel epigenetic agents for cancer treatment, Curr. Med. Chem., 20, 167, 10.2174/092986713804806667 · DOI
  125. Bhattacharyya, 2000, The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin, J. Biol. Chem., 275, 23899, 10.1074/jbc.C000276200 · DOI · Paper page
  126. Swisher, 2012, Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time, J. Natl. Cancer Inst., 104, 642, 10.1093/jnci/djs203 · DOI
  127. Konstantinopoulos, 2010, Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer, J. Clin. Oncol., 28, 3555, 10.1200/JCO.2009.27.5719 · DOI · Paper page
  128. Pennington, 2014, Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas, Clin. Cancer Res., 20, 764, 10.1158/1078-0432.CCR-13-2287 · DOI · Paper page
  129. Alsop, 2012, BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group, J. Clin. Oncol., 30, 2654, 10.1200/JCO.2011.39.8545 · DOI · Paper page
  130. Willers, 2009, Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies, Mol. Cancer Res., 7, 1304, 10.1158/1541-7786.MCR-09-0149 · DOI · Paper page
  131. Yin, 2012, RAP80 is critical in maintaining genomic stability and suppressing tumor development, Cancer Res., 72, 5080, 10.1158/0008-5472.CAN-12-1484 · DOI · Paper page

Cited by

See all 78

Metadata

Authors
Park, J.-Y., Zhang, F., & Andreassen, P. R.
Venue
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Publisher
Elsevier BV
Published
2014-08
Volume
1846
Issue
1
Pages
263-275
ISSN
0304-419X (ISSN-L)
OpenAlex
W2042787708
Cited by
78
References
29
FWCI
3.65
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
NIH (R01 HL085587)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PALB2: The hub of a network of tumor suppressors involved in DNA damage responses. https://app.cochat.ai/papers/10.1016/j.bbcan.2014.06.003
The paper
Park, J.-Y., Zhang, F., & Andreassen, P. R. (2014). PALB2: The hub of a network of tumor suppressors involved in DNA damage responses. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2014.06.003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.